11 results about "Chloroquinocin" patented technology

The invention discloses a synthesis method of 7-bromine-2-chloroquinoline-4-alcohol, which comprises the following steps of: converting 7-bromine-2, 4-dichloroquinoline serving as a raw material into 7-bromine-4-(tert-butoxy)-2-chloroquinoline, and reacting under the action of p-toluenesulfonic acid to obtain the 7-bromine-2-chloroquinoline-4-alcohol. The synthesis method of the 7-bromo-2-chloroquinoline-4-alcohol has the advantages of short steps, relatively mild reaction conditions and high product yield, not only provides a potential route for the process synthesis of the 7-bromo-2-chloroquinoline-4-alcohol, but also contributes to the development and utilization of quinoline compounds.

The invention belongs to the field of chemical analysis and testing, and particularly relates to a quinoline derivative coumarin fluorescent probe targeting tobramycin and a preparation method of the quinoline derivative coumarin fluorescent probe. The preparation method comprises the following steps: dissolving N1-(7-chloroquinoline-4-yl) ethane-1, 2-diamine and 7-(diethylamino) coumarin-3-formic acid in dichloromethane, adding condensing agents of 1-hydroxybenzotriazole (HOBT), 1-ethyl-(3-dimethylamino aldehyde) carbodiimide hydrochloride (EDCI) and triethylamine, carrying out a stirring reaction at room temperature, carrying out separation and purification on an obtained crude product through silica gel column chromatography, and carrying out recrystallization to obtain the 7-(diethylamino) coumarin-3-carboxylic acid-N-(7-chloroquinoline-4-yl) coumarin-3-carboxylic acid-N-(7-chloroquinoline-4-yl) coumarin-3-carboxylic acid-N-(7-chloroquinoline-4-yl) coumarin-3-carboxylic acid. The coumarin fluorescent probe DL containing the quinoline derivatives is obtained. The prepared coumarin fluorescent probe forms a complex under the participation of Cu < 2 + >, and tobramycin can be specifically and rapidly detected in deionized water.

The invention provides a preparation method and application of a targeted co-delivery system based on pMMP-1 and hydroxychloroquinoline, retinol with specific targeting to activated hepatic stellate cells is selected as a modification group, a targeted nano drug delivery system is obtained after a delivery carrier is modified, electronegative pMMP-1 is electrostatically adsorbed by utilizing the electropositive property of PR, and the targeted co-delivery system is obtained by utilizing the electronegative property of PR. An autophagy inhibitor HCQ is wrapped while electrostatic adsorption is carried out, so that a targeting co-delivery system which has an active targeting effect on aHSCs and is based on pMMP-1 and HCQ is obtained. The invention inhibits the autophagy of aHSCs, reduces the energy supply of activation of aHSCs, reduces the expression of fibrosis-related proteins, promotes the degradation of ECM, and blocks the promotion effect of mechanical force generated by ECM on the activation of HSCs. According to the present invention, the HSCs activation is inhibited while the ECM deposited outside the HSCs is degraded, such that the synergetic anti-hepatic fibrosis treatment effect is well achieved, the problems of complex hepatic fibrosis pathogenesis and poor effect of the single treatment means are solved, and the good clinical application prospect is provided.

The present invention discloses a method for synthesizing 4-chloroquinoline compounds, belonging to the technical field of organic synthesis. At room temperature, triphosgene and triphenylphosphine oxide are mixed and dissolved in an organic solvent. After stirring for 10 to 30 minutes, an N-aryl enamine compound is added. The reaction system is heated to 50 to 100 °C and stirring reaction is continued for 1 to 4 hours. The obtained reaction solution is post-treated to obtain 4-chloroquinoline compounds. By using the method of the present invention to synthesize 4-chloroquinoline compounds, the steps are few, the yield is high, and it is safer and more convenient than the traditional method using phosphorus chloride compounds.

This invention belongs to the pharmaceutical field, specifically relating to the synthesis of pharmaceutical intermediate compounds. Specifically, it relates to a method for preparing montelukast sodium using (E)-1-[3-(2-(7-chloroquinoline-2-yl)vinyl)phenyl]prop-2-en-1-ol and 2-(2-iodophenyl)prop-2-yl acetate as raw materials. This method not only has good impurity removal effects but also high product yield and purity. Furthermore, it does not require stringent synthesis conditions, making it suitable for large-scale industrial production.

The invention discloses a novel quinoline imidazole skeleton chiral nitrogen phosphine ligand compound as well as a synthesis method and application thereof. 2-chloroquinoline is used as an initial raw material, synthesis of a series of quinoline and imidazole skeleton compounds is realized through 3 # site iodination, C-N bond coupling, intramolecular cyclization reaction, C-P bond coupling and reduction reaction, and the quinoline and imidazole skeleton compounds are used as novel nitrogen phosphine ligands to realize asymmetric hydrogenation reaction of olefin to synthesize dexmedetomidine hydrochloride drug molecules. The method has the advantages of short synthesis route, high yield, good stereoselectivity and the like, and has good economic and social benefits.

The invention provides a synthesis method of 4, 7-dichloroquinoline, and relates to the technical field of compound preparation. Comprising the following steps: synthesizing 7-chloro-4-hydroxyquinoline-2-carboxylic acid by a one-pot method, and then carrying out decarboxylation and chlorination on the 7-chloro-4-hydroxyquinoline-2-carboxylic acid to obtain the 4, 7-dichloroquinoline. Wherein the step of synthesizing the 7-chloro-4-hydroxyquinoline-2-carboxylic acid by the one-pot method comprises the following steps: condensing m-chloroaniline and diethyl oxaloacetate to obtain a compound shown as a formula 3, directly adding condensation reaction liquid into an organic solvent, and heating and cyclizing to obtain 7-chloro-4-hydroxyquinoline-2-carboxylic acid ethyl ester; after the cyclization reaction is completed, sodium hydroxide is added for hydrolysis, and 7-chloro-4-hydroxyquinoline-2-carboxylic acid is obtained. The method has the advantages of simple operation, high productivity, safety, environmental protection, easily available raw materials, and suitableness for industrial production.

The application provides a preparation method and application of a targeting co-delivery system based on pMMP-1 and hydroxychloroquine. Retinol with specific targeting for activated hepatic stellate cells is selected as a modification group, a targeting nano drug delivery system is obtained after modification of a delivery carrier, and pMMP-1 with negative electricity is electrostatically adsorbed by using the positive electricity of PR, HCQ, an autophagy inhibitor, is wrapped at the same time of electrostatic adsorption, and a targeting co-delivery system based on pMMP-1 and HCQ with active targeting effect for aHSCs is obtained. The application inhibits autophagy of aHSCs, reduces energy supply for activation of aHSCs, reduces expression of fibrosis related proteins, promotes degradation of ECM, and blocks the promotion effect of mechanical force generated by ECM on activation of HSCs. The application not only inhibits activation of HSCs but also degrades ECM deposited outside HSCs, so that a synergistic anti-hepatic fibrosis treatment effect is better achieved, the problem of complex causes of hepatic fibrosis and poor effect of single treatment method is solved, and the application has a good clinical application prospect.

This invention discloses a continuous flow synthesis method for olutanib, belonging to the field of pharmaceutical synthesis technology. The method involves mixing a solution of 2-cyano-5-fluoropyridine with an acidic solution of hydrogen peroxide and reacting the mixture in a first continuous flow reactor at 70-90°C to obtain intermediate 3; mixing a solution of 3 with an acid anhydride and reacting the mixture in a second continuous flow reactor at 90-100°C to obtain intermediate 4; pumping a solution of 4 and a methylating agent into a third continuous flow packed bed reactor and reacting the solution at 20-25°C to obtain intermediate 5; and then reacting intermediate 5 with (… S A solution of 3-(1-aminoethyl)-6-chloroquinoline-2(1H)-one was pumped into a fourth continuous flow packed bed reactor and reacted at 90-95°C. The resulting product was then purified to obtain olutanib. The total residence time of this method is only 118 minutes, eliminating the need for column chromatography purification. The process is continuous, safe, and controllable, with high production efficiency and ease of scale-up.

The application discloses a preparation method of 3,7-dichloro-8-methylquinoline, which comprises the following steps: taking 3-chloro-2-methylphenylamine as raw material, and performing one-step or two-step cyclization reaction on the 3-chloro-2-methylphenylamine by chloro-substituted propyl aldehyde or chloro-substituted propyl aldehyde to prepare 3,7-dichloro-8-methylquinoline; the 3,7-dichloro-8-methylquinoline prepared by the method has high yield. The application further discloses application of the 3,7-dichloro-8-methylquinoline prepared by the preparation method in preparation of 3,7-dichloro-8-quinoline carboxylic acid; since the quinoline ring of the raw material 3,7-dichloro-8-methylquinoline is already substituted by chlorine, only free radical reaction of a side chain of the quinoline ring occurs during chlorination, and thus the method has good selectivity and high purity.

The application belongs to the field of enzyme catalysis, and particularly relates to optimization of an improved carbonyl reductase sequence, construction of an engineering bacterium and application of the engineering bacterium in catalysis of a montelukast sodium intermediate. The application provides a carbonyl reductase and an engineering bacterium, wherein the bacterium takes (E)-2-(3-(3-(2-(7-chloro-2-quinolinyl)vinyl)phenyl)-3-oxopropyl)benzoic acid methyl ester as a starting substrate, realizes efficient synthesis of a product S-(E)-2-(3-(3-(2-(7-chloro-2-quinolinyl)vinyl)phenyl)-3-hydroxypropyl)benzoic acid methyl ester in the presence of the carbonyl reductase, and solves problems of low substrate concentration, high production cost and long conversion time in a traditional method, wherein a substrate conversion rate is greater than or equal to 99.6%, a molar yield reaches 95%, and a product chiral purity reaches 100%.